Literature DB >> 24575173

Therapeutic interventions for heart failure with preserved ejection fraction: A summary of current evidence.

Muhammad Asrar ul Haq1, Chiew Wong1, Vivek Mutha1, Nagesh Anavekar1, Kwang Lim1, Peter Barlis1, David L Hare1.   

Abstract

Heart failure with preserved ejection fraction (HFPEF) is common and represents a major challenge in cardiovascular medicine. Most of the current treatment of HFPEF is based on morbidity benefits and symptom reduction. Various pharmacological interventions available for heart failure with reduced ejection fraction have not been supported by clinical studies for HFPEF. Addressing the specific aetiology and aggressive risk factor modification remain the mainstay in the treatment of HFPEF. We present a brief overview of the currently recommended therapeutic options with available evidence.

Entities:  

Keywords:  Diastolic dysfunction; Heart failure; Heart failure with normal ejection fraction; Heart failure with preserved ejection fraction

Year:  2014        PMID： 24575173      PMCID： PMC3935061          DOI： 10.4330/wjc.v6.i2.67

Source DB:  PubMed          Journal:  World J Cardiol


  85 in total

Review 1.  Clinical practice. Diastolic heart failure.

Authors:  Gerard P Aurigemma; William H Gaasch
Journal:  N Engl J Med       Date:  2004-09-09       Impact factor: 91.245

2.  2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation.

Authors:  Mariell Jessup; William T Abraham; Donald E Casey; Arthur M Feldman; Gary S Francis; Theodore G Ganiats; Marvin A Konstam; Donna M Mancini; Peter S Rahko; Marc A Silver; Lynne Warner Stevenson; Clyde W Yancy
Journal:  Circulation       Date:  2009-03-26       Impact factor: 29.690

Review 3.  Calcium mishandling in diastolic dysfunction: mechanisms and potential therapies.

Authors:  Michelle L Asp; Joshua J Martindale; Frazer I Heinis; Wang Wang; Joseph M Metzger
Journal:  Biochim Biophys Acta       Date:  2012-09-27

4.  Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure.

Authors:  Jasper W L Hartog; Suzan Willemsen; Dirk J van Veldhuisen; Jan L Posma; Leen M van Wijk; Yoran M Hummel; Hans L Hillege; Adriaan A Voors
Journal:  Eur J Heart Fail       Date:  2011-06-13       Impact factor: 15.534

5.  1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction).

Authors:  T J Ryan; E M Antman; N H Brooks; R M Califf; L D Hillis; L F Hiratzka; E Rapaport; B Riegel; R O Russell; E E Smith; W D Weaver; R J Gibbons; J S Alpert; K A Eagle; T J Gardner; A Garson; G Gregoratos; T J Ryan; S C Smith
Journal:  J Am Coll Cardiol       Date:  1999-09       Impact factor: 24.094

6.  Home-based exercise improves functional performance and quality of life in women with diastolic heart failure.

Authors:  Rebecca A Gary; Carla A Sueta; Molly Dougherty; Beth Rosenberg; Dennis Cheek; John Preisser; Virginia Neelon; Robert McMurray
Journal:  Heart Lung       Date:  2004 Jul-Aug       Impact factor: 2.210

7.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

Authors:  Margaret M Redfield; Horng H Chen; Barry A Borlaug; Marc J Semigran; Kerry L Lee; Gregory Lewis; Martin M LeWinter; Jean L Rouleau; David A Bull; Douglas L Mann; Anita Deswal; Lynne W Stevenson; Michael M Givertz; Elizabeth O Ofili; Christopher M O'Connor; G Michael Felker; Steven R Goldsmith; Bradley A Bart; Steven E McNulty; Jenny C Ibarra; Grace Lin; Jae K Oh; Manesh R Patel; Raymond J Kim; Russell P Tracy; Eric J Velazquez; Kevin J Anstrom; Adrian F Hernandez; Alice M Mascette; Eugene Braunwald
Journal:  JAMA       Date:  2013-03-27       Impact factor: 56.272

8.  Congestive heart failure symptoms in patients with preserved left ventricular systolic function: analysis of the CASS registry.

Authors:  K W Judge; Y Pawitan; J Caldwell; B J Gersh; J W Kennedy
Journal:  J Am Coll Cardiol       Date:  1991-08       Impact factor: 24.094

9.  Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy.

Authors:  Francesco S Loffredo; Matthew L Steinhauser; Steven M Jay; Joseph Gannon; James R Pancoast; Pratyusha Yalamanchi; Manisha Sinha; Claudia Dall'Osso; Danika Khong; Jennifer L Shadrach; Christine M Miller; Britta S Singer; Alex Stewart; Nikolaos Psychogios; Robert E Gerszten; Adam J Hartigan; Mi-Jeong Kim; Thomas Serwold; Amy J Wagers; Richard T Lee
Journal:  Cell       Date:  2013-05-09       Impact factor: 41.582

Review 10.  New treatment options for late Na current, arrhythmias, and diastolic dysfunction.

Authors:  Lars S Maier
Journal:  Curr Heart Fail Rep       Date:  2012-09
View more
  10 in total

1.  Concomitant coronary and renal revascularization improves left ventricular hypertrophy more than coronary stenting alone in patients with ischemic heart and renal disease.

Authors:  Hao-jian Dong; Cheng Huang; De-mou Luo; Jing-guang Ye; Jun-qing Yang; Guang Li; Jian-fang Luo; Ying-ling Zhou
Journal:  J Zhejiang Univ Sci B       Date:  2016-01       Impact factor: 3.066

Review 2.  Heart failure with preserved ejection fraction - unwinding the diagnosis mystique.

Authors:  Muhammad Asrar Ul Haq; Vivek Mutha; Nima Rudd; David L Hare; Chiew Wong
Journal:  Am J Cardiovasc Dis       Date:  2014-10-11

3.  Alternative Splicing of Titin Restores Diastolic Function in an HFpEF-Like Genetic Murine Model (TtnΔIAjxn).

Authors:  Mathew Bull; Mei Methawasin; Joshua Strom; Pooja Nair; Kirk Hutchinson; Henk Granzier
Journal:  Circ Res       Date:  2016-07-28       Impact factor: 17.367

4.  Mast Cell Inhibition Attenuates Cardiac Remodeling and Diastolic Dysfunction in Middle-aged, Ovariectomized Fischer 344 × Brown Norway Rats.

Authors:  Hao Wang; Jaqueline da Silva; Allan Alencar; Gisele Zapata-Sudo; Marina R Lin; Xuming Sun; Sarfaraz Ahmad; Carlos M Ferrario; Leanne Groban
Journal:  J Cardiovasc Pharmacol       Date:  2016-07       Impact factor: 3.105

5.  Obesity and metabolic features associated with long-term developing diastolic dysfunction in an initially healthy population-based cohort.

Authors:  Kénora Chau; Nicolas Girerd; Martin Magnusson; Zohra Lamiral; Erwan Bozec; Ludovic Merckle; Margret Leosdottir; Erasmus Bachus; Zied Frikha; João Pedro Ferreira; Jean-Pierre Després; Patrick Rossignol; Jean-Marc Boivin; Faiez Zannad
Journal:  Clin Res Cardiol       Date:  2018-04-21       Impact factor: 5.460

6.  Treating Heart Failure with Preserved Ejection Fraction: A Challenge for Clinicians.

Authors:  Patricia A Howard
Journal:  Hosp Pharm       Date:  2015-06

Review 7.  Clinical utility of exercise training in heart failure with reduced and preserved ejection fraction.

Authors:  Muhammad Asrar Ul Haq; Cheng Yee Goh; Itamar Levinger; Chiew Wong; David L Hare
Journal:  Clin Med Insights Cardiol       Date:  2015-02-09

Review 8.  Heart Failure with Preserved Ejection Fraction - Concept, Pathophysiology, Diagnosis and Challenges for Treatment.

Authors:  Lidija Veterovska Miljkovik; Vera Spiroska
Journal:  Open Access Maced J Med Sci       Date:  2015-07-28

9.  Effect of Valsartan on Sarcoplasmic Reticulum Ca2+-ATPase Pump of the Left Ventricular Myocardium in Rats with Heart Failure with Preserved Ejection Fraction.

Authors:  Xiao Ying; Long Weiqing; Lu Guihua; Zhang Juhong; Zhibin Huang
Journal:  Biomed Hub       Date:  2016-07-30

10.  Study protocol, randomized controlled trial: reducing symptom burden in patients with heart failure with preserved ejection fraction using ubiquinol and/or D-ribose.

Authors:  Janet D Pierce; Diane E Mahoney; John B Hiebert; Amanda R Thimmesch; Francisco J Diaz; Carol Smith; Qiuhua Shen; Dinesh Pal Mudaranthakam; Richard L Clancy
Journal:  BMC Cardiovasc Disord       Date:  2018-04-02       Impact factor: 2.298
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.